Madeleine Welsh
YOU?
Author Swipe
View article: 9286 RZ358 Therapy. A Novel Approach To Hyperinsulinemia In Metastatic Neuroendocrine Tumor Patients
9286 RZ358 Therapy. A Novel Approach To Hyperinsulinemia In Metastatic Neuroendocrine Tumor Patients Open
Disclosure: J. Noreña: None. T. Akcan: None. S. Patel: None. M. Welsh: None. S. Shaheen: None. M. Tan: None. RZ358, an intravenously administered monoclonal antibody, targets a unique allosteric site on the insulin receptor. It is under in…
View article: 9286 RZ358 Therapy. A Novel Approach to Hyperinsulinemia in Metastatic Neuroendocrine Tumor Patients
9286 RZ358 Therapy. A Novel Approach to Hyperinsulinemia in Metastatic Neuroendocrine Tumor Patients Open
Disclosure: J. Noreña: None. T. Akcan: None. S. Patel: None. M. Welsh: None. S. Shaheen: None. M. Tan: None. RZ358, an intravenously administered monoclonal antibody, targets a unique allosteric site on the insulin receptor. It is under in…
View article: Carboplatin and paclitaxel after <scp>anti‐PD</scp>‐1 or <scp>anti‐PD‐L1</scp> antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck
Carboplatin and paclitaxel after <span>anti‐PD</span>‐1 or <span>anti‐PD‐L1</span> antibody therapy in recurrent and/or metastatic squamous cell carcinoma of head and neck Open
Background The impact of concurrent chemotherapy and immunotherapy has been well characterized in patients with recurrent and metastatic head and neck squamous cell carcinoma (RM‐SCCHN). Here, we report outcomes in patients treated sequent…
View article: 201 Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma
201 Carboplatin, paclitaxel and pembrolizumab for the first line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma Open
Background A recent phase III study (Keynote-048) demonstrated survival benefit of platinum, 5-FU and pembrolizumab in 1st line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (RM-HNSCC).1 However,…